SAN DIEGO, CA AND TORONTO, Sept. 25,
2014 /PRNewswire/ - Aptose Biosciences Inc. (TSX: APS), a
clinical-stage company developing new therapeutics and molecular
diagnostics that target the underlying mechanisms of cancer, today
announced that William G. Rice,
Ph.D., Chairman, President and Chief Executive Officer, will
present at two upcoming conferences in Europe:
- 14th Annual BIOTECH IN EUROPE FORUM For Global Partnering &
Investment
Congress Center Basel, Basel,
Switzerland
10:45AM CET on Tuesday September 30, 2014 - Darwin Room
- EPIC Biotech 2014
The King's Fund, London, UK
4:10PM GMT on Thursday, October 1, 2014 - Burdette Theatre
About Aptose Biosciences
Aptose Biosciences (formerly Lorus Therapeutics
Inc.) is a clinical-stage biotechnology company committed to
discovering and developing personalized therapies addressing unmet
medical needs in oncology. Aptose is advancing new
therapeutics focused on novel cellular targets on the leading edge
of cancer research coupled with companion diagnostics to identify
the optimal patient population for our products. Aptose's
lead anticancer agent APTO-253 is in clinical development.
The company's small molecule cancer therapeutics pipeline includes
products designed to provide additive or synergistic efficacy with
existing anti-cancer therapies and regimens without overlapping
toxicities.
Forward Looking Statements
This press release contains forward-looking
statements within the meaning of Canadian and U.S. securities laws.
Such statements include, but are not limited to, statements
relating to the Company's plans, objectives, expectations and
intentions and other statements including words such as "continue",
"expect", "intend", "will", "should", "would", "may", and other
similar expressions. Such statements reflect our current views with
respect to future events and are subject to risks and uncertainties
and are necessarily based upon a number of estimates and
assumptions that, while considered reasonable by us are inherently
subject to significant business, economic, competitive, political
and social uncertainties and contingencies. Many factors could
cause our actual results, performance or achievements to be
materially different from any future results, performance or
achievements described in this press release. Such expressed or
implied forward looking statements could include, among others: our
ability to obtain the capital required for research and operations;
the inherent risks in early stage drug development including
demonstrating efficacy; development time/cost and the regulatory
approval process; the progress of our clinical trials; our ability
to find and enter into agreements with potential partners; our
ability to attract and retain key personnel; changing market
conditions; and other risks detailed from time-to-time in our
ongoing quarterly filings, annual information forms, annual reports
and annual filings with Canadian securities regulators and the
United States Securities and Exchange Commission.
Should one or more of these risks or
uncertainties materialize, or should the assumptions set out in the
section entitled "Risk Factors" in our filings with Canadian
securities regulators and the United States Securities and Exchange
Commission underlying those forward-looking statements prove
incorrect, actual results may vary materially from those described
herein. These forward-looking statements are made as of the date of
this press release and we do not intend, and do not assume any
obligation, to update these forward-looking statements, except as
required by law. We cannot assure you that such statements will
prove to be accurate as actual results and future events could
differ materially from those anticipated in such statements.
Investors are cautioned that forward-looking statements are not
guarantees of future performance and accordingly investors are
cautioned not to put undue reliance on forward-looking statements
due to the inherent uncertainty therein.
SOURCE Aptose Biosciences Inc.
